STADA
STADA's Spanish subsidiary develops, manufactures, and markets generic medicines, biosimilars, and Consumer Health brands across 700+ presentations and multiple OTC brands. It serves pharmacies, hospitals, and patients through direct sales and the STADA+activA platform.
- Company typePrivate
- Founded1895
- HeadquartersSant Just Desvern, Spain
- Headcount—
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What STADA does
LABORATORIO STADA, S.L.U. operates as the Spanish subsidiary of STADA Arzneimittel AG, a German-headquartered pharmaceutical group founded in 1895 and listed on the Frankfurt Stock Exchange. The Spanish entity, based in Sant Just Desvern with a secondary office in Madrid, develops, manufactures, and markets a portfolio organized across three pillars: (1) generic medicines and hospital pharmaceuticals comprising more than 700 presentations across broad therapeutic areas, identified by the EFG (Equivalente Farmacéutico Genérico) designation; (2) biosimilars used to treat serious conditions including osteoporosis, arthritis, and cancer, priced 20-25% below reference biologics; and (3) Consumer Health brands spanning non-prescription categories such as venous circulation (Venoruton), stretch marks (Trofolastin), probiotics (Lactoflora), sun protection (Ladival), dermatological care (Mitosyl), and general health (Care+, Neositrin). Other pharmaceutical brands include Hirudoid, Algesal, Clinadil, Kefloridina Forte, Idoka, Reusin, and Orlidunn.
The technical foundation centers on pharmaceutical manufacturing quality controls covering identity, content, and purity testing for active ingredients and finished products, complemented by the proprietary STADA ValuePack packaging system that uses color-coded therapeutic group identification, real pharmaceutical-form photography, and five-sided labeling to reduce dispensing errors. The company monetizes through one-time unit sales of pharmaceuticals at regulated Spanish prices (e.g., Quetiapina STADA 50mg 60 comprimidos at PVP IVA €16.20), with biosimilars offered at a structural discount to originator biologics and Consumer Health products sold at retail pharmacy margins.
STADA's go-to-market is hybrid: dedicated direct sales forces target pharmacies (SMB buyers) and hospitals (enterprise buyers), while consumer brands reach end-patients through pharmacy shelves. The STADA+activA customer portal provides pharmacy account management, product access, and pharmacovigilance channels for healthcare professional engagement, supplementing direct sales relationships. Distribution spans approximately 120 countries globally through the parent group's subsidiaries and distribution partnerships, with Spain served directly by LABORATORIO STADA. The company is a voluntary member of AESEG (Asociación Española de Medicamentos Genéricos), committing to the Spanish generic industry's Code of Conduct on healthcare community interactions.
STADA firmographics
Firmographics- Name
- STADA
- Legal name
- LABORATORIO STADA, S.L.U.
- Website
- https://stada.es
- Company type
- Private
- Founded year
- 1895
- Operating status
- Operating
- Short description
- STADA's Spanish subsidiary develops, manufactures, and markets generic medicines, biosimilars, and Consumer Health brands across 700+ presentations and multiple OTC brands. It serves pharmacies, hospitals, and patients through direct sales and the STADA+activA platform.
- Ownership category
- akta.pro rank
STADA industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where STADA is headquartered
LocationHeadquarters
- HQ city
- Sant Just Desvern
- HQ country
- Spain
- HQ region
- Europe
Offices3 records
Markets served
STADA business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Generic Medications: Production and sale of generic pharmaceutical products including more than 700 presentations covering multiple therapeutic areas. Revenue generated from pharmacy and hospital sales.
- Biosimilars: Biotechnologically produced medications equivalent in quality, efficacy and safety to reference biological medicines. Used for treatment of serious diseases including osteoporosis, arthritis and cancer.
- Consumer Health Products: Sale of OTC and consumer health brands including Venoruton, Trofolastin, Lactoflora, Ladival, Care+, Neositrin, and Mitosyl through pharmacies.
- Hospital Pharmaceuticals: Specialized hospital medications and products for healthcare facility use.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Generic medication - Quetiapina STADA 50mg example |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
STADA product offering
Product offeringCore offering
STADA develops, manufactures, and markets generic medicines, specialty hospital pharmaceuticals, and biosimilars, alongside a portfolio of branded Consumer Health OTC products. In Spain, the generic portfolio spans more than 700 presentations across multiple therapeutic areas, while Consumer Health brands (Venoruton, Trofolastin, Lactoflora, Ladival, Care+, Neositrin, Mitosyl) rank among the best-selling products in their respective categories. Products are sold primarily through pharmacy and hospital channels, with biosimilars priced 20–25% below reference biological medicines.
Product overview
STADA's Spain operations are organized around three strategic pillars: (1) generic medicines and hospital pharmaceuticals — a portfolio of more than 700 presentations across broad therapeutic areas, supported by the STADA ValuePack packaging system (e.g., Quetiapine STADA 50mg); (2) biosimilars — biotechnologically produced equivalents to reference biologics used in treating serious conditions such as osteoporosis, arthritis, and cancer, priced 20–25% below reference products; and (3) Consumer Health brands — a portfolio of non-prescription health and wellness brands including Trofolastin® (stretch marks), Venoruton® (venous circulation), Lactoflora® (probiotics/digestive health), Ladival® (sun protection), Care+® (health and wellness), Mitosyl® (dermatological care), Neositrin® (healthcare), and STADAPHARM (pharmaceutical brand). STADA+activA is a client-facing portal for pharmacists and healthcare professionals to manage accounts and access STADA's offerings.
Differentiator
Problem solved
Functional benefit
Brands
- Venoruton: Consumer health brand for vein care products
- Trofolastin
- Lactoflora
- Ladival
- Care+
- Neositrin
- Mitosyl
- Hirudoid
- Algesal
- Clinadil
- Kefloridina Forte
- Idoka
- Reusin
- Orlidunn
- STADAPHARM
Products and services
- STADA Generic Medicines and Hospital Pharmaceuticals STADA's core generic medicines portfolio in Spain, comprising more than 700 presentations across a broad range of therapeutic areas, including hospital-exclusive specialty pharmaceuticals. Generics are chemically produced equivalents to originator drugs, recognized by the EFG (Equivalente Farmacéutico Genérico) designation on labeling.
- STADA Biosimilars Biotechnologically produced medicines equivalent in quality, efficacy, and safety to a reference biological medicine, used in the treatment of serious conditions such as osteoporosis, arthritis, and cancer, and priced 20–25% below the reference product.
- Trofolastin Topical Consumer Health brand for the prevention and treatment of stretch marks; among the best-selling products in its category in Spain.
- Venoruton Consumer Health brand for venous circulation support; among the best-selling products in its category in Spain.
- Lactoflora Consumer Health brand for probiotic and digestive health support; among the best-selling products in its category in Spain.
- Ladival Consumer Health brand focused on sun protection skincare products.
- Care+ Consumer Health brand covering a range of health and wellness products; among the best-selling in its category in Spain.
- Neositrin Consumer Health brand; among the best-selling in its category in Spain.
- Mitosyl Consumer Health brand for dermatological care; among the best-selling products in its category in Spain.
- Hirudoid Topical pharmaceutical product for the treatment of hematomas and bruises.
- Algesal Topical analgesic pharmaceutical product for pain relief.
- Kefloridina Forte Antibiotic pharmaceutical product.
- Reusin Pharmaceutical product.
- Idoka Dental care pharmaceutical product.
- STADA+activA Client portal and loyalty program for pharmacists and healthcare professionals providing pharmacy management tools, product information access, and services to support dispensing of STADA's portfolio.
Quantifiable outcome
- Biosimilars priced 20-25% lower than reference biological medicines
- +1 more outcomes
Companies that use STADA
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
STADA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
STADA partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AESEG (Asociación Española de Medicamentos Genéricos)coreSTADA is a voluntary member of AESEG and commits to the Code of Conduct on interactions with the Healthcare Community. STADA publishes value transfers to Healthcare Organizations, Health Professionals, and Patient Organizations in compliance with the code. This membership ensures ethical business practices in line with industry standards.
Scale indicators3 records
Recent moves6 records
Expansion highlights8 records
STADA competitors and assessment
Company assessmentDirect peers
- Kern Pharma: Spanish generic pharmaceutical manufacturer headquartered in Barcelona. Direct competitor in the Spanish generic medicines market with overlapping therapeutic areas and pharmacy distribution channels.
- Viatris: Global pharmaceutical company formed from Mylan-Upjohn merger with focus on generics, biosimilars, and branded pharmaceuticals. Comparable to STADA in product portfolio breadth and generic market positioning across European markets.
- Sandoz (Novartis): One of the world's largest generic and biosimilar pharmaceutical companies. Directly competes with STADA in generics, biosimilars, and consumer health across European markets with similar portfolios and pricing strategies.
- Faes Farma: Spanish pharmaceutical company with prescription, OTC consumer health, and animal health divisions. Direct peer in Spain with overlapping consumer health brands and pharmaceutical distribution models.
- Almirall: Spanish pharmaceutical company headquartered in Barcelona focused on dermatology and specialty pharmaceuticals. Direct peer in the Spanish market with overlapping consumer health and prescription pharmaceutical businesses.
- Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals and biosimilars with extensive portfolio across multiple therapeutic areas. Directly comparable to STADA as both are major generic manufacturers with biosimilar programs and significant consumer health divisions.
- Cinfa: Spanish pharmaceutical company focused on generic medicines and consumer health products. Direct peer in the Spanish market with similar generic and OTC consumer health business model.
- Laboratorios Rovi: Spanish pharmaceutical company specializing in prescription and OTC products, including biosimilars and hospital injectables. Strong direct peer in the Spanish market with similar generic and specialty pharma focus.
- Zentiva: European generic pharmaceutical company headquartered in Prague with strong presence across EU markets. Direct peer in generics and consumer health with similar geographic footprint and cost-pressured healthcare system focus.
Emerging players
- Aurobindo Pharma: Indian-headquartered global generic pharmaceutical manufacturer with European presence. Comparable in generic pharmaceutical manufacturing scale and biosimilar development, with growing European market penetration.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
STADA social profiles
Digital presenceSTADA financial estimates
Financial estimateRevenue estimate
Valuation estimate
STADA leadership team
Management profileNumber of profiles
Profiles3 records
STADA subsidiaries and ownership
Company hierarchySubsidiaries1 record
STADA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
STADA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about STADA
What does STADA do?
STADA develops, manufactures, and markets generic medicines, specialty hospital pharmaceuticals, and biosimilars, alongside a portfolio of branded Consumer Health OTC products. In Spain, the generic portfolio spans more than 700 presentations across multiple therapeutic areas, while Consumer Health brands (Venoruton, Trofolastin, Lactoflora, Ladival, Care+, Neositrin, Mitosyl) rank among the best-selling products in their respective categories. Products are sold primarily through pharmacy and hospital channels, with biosimilars priced 20–25% below reference biological medicines.
Is STADA a public or private company?
STADA is a private company. It is classified as public and is currently operating.
When was STADA founded?
STADA was founded in 1895.
Where is STADA based?
STADA is headquartered in Sant Just Desvern, Spain, in the Europe region.
How does STADA make money?
Four revenue lines are on record. Generic Medications are the primary driver. The others are biosimilars, consumer Health Products and hospital Pharmaceuticals.
Who are STADA's main competitors?
Direct peers on record are Kern Pharma, Viatris, Sandoz (Novartis), Faes Farma, Almirall, Teva Pharmaceutical Industries, Cinfa, Laboratorios Rovi and Zentiva. Aurobindo Pharma is listed as an emerging player.
Does STADA have an API?
No public API is recorded for STADA.
What industry is STADA in?
STADA's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.